These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 19401540)

  • 1. Antifibrillatory agents and potassium channels in the atria: pore block versus channel trafficking.
    McEwen DP; Martens JR
    Mol Interv; 2009 Apr; 9(2):79-86. PubMed ID: 19401540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-channel drugs to prevent atrial fibrillation].
    Fazekas T; Liszkai G
    Orv Hetil; 2005 Nov; 146(45):2287-94. PubMed ID: 16304807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Electrophysiological characterization and antiarrhythmic efficacy of the mixed potassium channel-blocking antiarrhythmic agent AZ13395438 in vitro and in vivo.
    Jacobson I; Duker G; Florentzson M; Linhardt G; Lindhardt E; Nordkam AK; Åstrand A; Carlsson L
    J Cardiovasc Pharmacol Ther; 2013 May; 18(3):290-300. PubMed ID: 23307834
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atrial-selective K
    Ravens U
    Can J Physiol Pharmacol; 2017 Nov; 95(11):1313-1318. PubMed ID: 28738160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiac ion channels and mechanisms for protection against atrial fibrillation.
    Grunnet M; Bentzen BH; Sørensen US; Diness JG
    Rev Physiol Biochem Pharmacol; 2012; 162():1-58. PubMed ID: 21987061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New antiarrhythmic agents for atrial fibrillation and atrial flutter.
    Pecini R; Elming H; Pedersen OD; Torp-Pedersen C
    Expert Opin Emerg Drugs; 2005 May; 10(2):311-22. PubMed ID: 15934869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multiple ion channel blocker, NIP-142, for the treatment of atrial fibrillation.
    Tanaka H; Hashimoto N
    Cardiovasc Drug Rev; 2007; 25(4):342-56. PubMed ID: 18078434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a highly selective acetylcholine-activated K+ channel blocker on experimental atrial fibrillation.
    Machida T; Hashimoto N; Kuwahara I; Ogino Y; Matsuura J; Yamamoto W; Itano Y; Zamma A; Matsumoto R; Kamon J; Kobayashi T; Ishiwata N; Yamashita T; Ogura T; Nakaya H
    Circ Arrhythm Electrophysiol; 2011 Feb; 4(1):94-102. PubMed ID: 21156770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Inhibition of the muscarinic potassium current by KB130015, a new antiarrhythmic agent to treat atrial fibrillation].
    Borchard R; van Bracht M; Wickenbrock I; Prull MW; Pott L; Trappe HJ
    Med Klin (Munich); 2005 Nov; 100(11):697-703. PubMed ID: 16328176
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New pharmacological targets and treatments for atrial fibrillation.
    Carlsson L; Duker G; Jacobson I
    Trends Pharmacol Sci; 2010 Aug; 31(8):364-71. PubMed ID: 20605645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Restoration and maintenance of sinus rhythm in patients with atrial fibrillation. New pharmacological approaches].
    Runge S; Dietz R; Haverkamp W
    Dtsch Med Wochenschr; 2008 Dec; 133(49):2572-8. PubMed ID: 19039713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of cardiac two-pore-domain K+ (K2P) channels--an emerging antiarrhythmic concept.
    Schmidt C; Wiedmann F; Schweizer PA; Katus HA; Thomas D
    Eur J Pharmacol; 2014 Sep; 738():250-5. PubMed ID: 24927994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of I
    Juhász V; Hornyik T; Benák A; Nagy N; Husti Z; Pap R; Sághy L; Virág L; Varró A; Baczkó I
    Can J Physiol Pharmacol; 2018 Jan; 96(1):18-25. PubMed ID: 28892643
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockers of the Kv1.5 channel for the treatment of atrial arrhythmias.
    Brendel J; Peukert S
    Curr Med Chem Cardiovasc Hematol Agents; 2003 Oct; 1(3):273-87. PubMed ID: 15326917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The emerging role of antiarrhythmic compounds with atrial selectivity in the management of atrial fibrillation.
    McBride BF
    J Clin Pharmacol; 2009 Mar; 49(3):258-67. PubMed ID: 19246727
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting cardiac potassium channels for state-of-the-art drug discovery.
    Walsh KB
    Expert Opin Drug Discov; 2015 Feb; 10(2):157-69. PubMed ID: 25400064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inward rectifier potassium currents as a target for atrial fibrillation therapy.
    Ehrlich JR
    J Cardiovasc Pharmacol; 2008 Aug; 52(2):129-35. PubMed ID: 18670367
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate-Dependent Role of I
    Aguilar M; Feng J; Vigmond E; Comtois P; Nattel S
    Biophys J; 2017 May; 112(9):1997-2010. PubMed ID: 28494969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacotherapy of atrial fibrillation: a pathophysiological perspective and review.
    Jacob S; Ali OA; Pidlaoan V; Badheka AO; Kerin NZ
    Am J Ther; 2011 May; 18(3):241-60. PubMed ID: 20861719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker, (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate.
    Regan CP; Wallace AA; Cresswell HK; Atkins CL; Lynch JJ
    J Pharmacol Exp Ther; 2006 Feb; 316(2):727-32. PubMed ID: 16243963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.